Clinical Trials on Ovarian Neoplasms in Belgium

Total 3713 results

Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Boehringer Ingelheim

Completed

Secondary Prevention of Venous Thrombo Embolism (VTE). (RE-MEDY)

Thromboembolism

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Russian... and more
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
Eisai Limited

Completed

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Poland, France, Spain, Germany, Hungary, Italy, Estonia, South Africa, Belgium, United Kingdom, Portugal, Austria, Czech Republic, Israel, Lithuania, Serbia, Sweden
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
IVERIC bio, Inc.

Completed

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Macular Degeneration | Geographic Atrophy

United States, Spain, France, Germany, Austria, Belgium, Israel, Poland, Canada, Italy, Estonia, Australia, United Kingdom, Hungary, Argentina, Brazil, Colombia, Croatia, Czechia, Latvia
Hoffmann-La Roche

Terminated

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)

Geographic Atrophy

Canada, United States, Belgium, Peru, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Poland, Slovakia, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
University College Dublin
Universitaire Ziekenhuizen KU Leuven; National University of Ireland, Galway... and other collaborators

Active, not recruiting

Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE)

Stroke | Ischemic Attack, Transient

Ireland, United Kingdom, Spain, Germany, Belgium, Denmark, Netherlands, Switzerland, Estonia, Canada, Portugal, Poland, Lithuania, Czechia
Genmab
AbbVie

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Belgium, Brazil, China, United States, Canada and more
Hoffmann-La Roche

Terminated

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)

Geographic Atrophy

United States, United Kingdom, Netherlands, Germany, Belgium, Poland, Spain, Argentina, Australia, Hungary, Italy, Portugal, France, Turkey, Austria, Russian Federation, Mexico, Peru, Denmark, Slovakia, Sweden, Switzerland
Acorda Therapeutics

Completed

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Idiopathic Parkinson's Disease

United States, Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Serbia, Spain, United Kingdom
Pfizer

Completed

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

Urothelial Cancer

Australia, France, Spain, United States, Canada, Netherlands, Taiwan, Belgium, Denmark, Argentina, Italy, Israel, Japan, Korea, Republic of, Brazil, Serbia, Norway, New Zealand, Hungary, Czechia, India, Mexico, Portugal, Russian Federation and more
Pfizer

Completed

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

France, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
AbbVie

Active, not recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

Myelofibrosis (MF)

United States, Australia, Belgium, Bulgaria, Canada, Croatia, France, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (RETAIN)

Diabetic Macular Edema

Belgium, United Kingdom, Netherlands, Ireland, Switzerland, Italy, Hungary, France, Spain, Portugal, Poland, Czech Republic, Greece
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
GlaxoSmithKline

Completed

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Thrombosis, Venous

Netherlands, Belgium, Germany, Canada, Slovenia, Italy, Hungary, Poland, Russian Federation, Czech Republic, France
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
Novartis Pharmaceuticals

Completed

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)

Tuberous Sclerosis Complex-associated Refractory Seizures

United States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
GlaxoSmithKline

Completed

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Herpes Zoster

France, Spain, Taiwan, Belgium, Singapore, United States, Hong Kong, Russian Federation, Finland, Korea, Republic of, Czechia, Australia, Canada, Sweden, Poland, United Kingdom, Panama, Italy, Turkey, Pakistan, New Zealand
Hoffmann-La Roche

Terminated

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Geographic Atrophy

United States, United Kingdom, Germany, France, Turkey, Australia, Austria, Belgium, Canada, Denmark, Hungary, Italy, Poland, Slovakia, Spain, Switzerland, Portugal, Netherlands, Peru
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
CENTOGENE GmbH Rostock

Recruiting

Rostock International Parkinson's Disease Study (ROPAD) (ROPAD)

Parkinson´s Disease

Spain, Israel, United Kingdom, United States, Germany, Albania, Belgium, Brazil, Canada, France, Greece, Italy, Portugal, Turkey, Norway
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Newron Pharmaceuticals SPA

Completed

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (SETTLE)

Idiopathic Parkinson's Disease

Korea, Republic of, Israel, Thailand, New Zealand, Spain, Canada, United States, Switzerland, Netherlands, Taiwan, United Kingdom, Belgium, Estonia, Germany, Hungary, India, Australia, Austria, France, Malaysia, Slovakia
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Myelodysplastic Syndrome

Australia, United States, Canada, Spain, Belgium, France, Czechia, Italy, Korea, Republic of, Israel, Brazil, China, Germany, Turkey, Japan, Greece, Poland, United Kingdom, Russian Federation, Mexico
Bristol-Myers Squibb

Completed

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myeloid Leukemia, Chronic, Accelerated Phase

Australia, Canada, France, Germany, Italy, Korea, Republic of, Taiwan, Thailand, United States, Spain, Austria, Denmark, Belgium, Sweden, Switzerland, Netherlands, Peru, South Africa, Philippines, Singapore, Russian Federation, Br... and more
Novartis Pharmaceuticals

Active, not recruiting

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Relapsing Multiple Sclerosis

United States, Poland, Austria, Belgium, Czechia, Germany, Australia, Switzerland, Lebanon, Argentina, Canada, Slovenia, Bulgaria, Latvia, Russian Federation, Spain, Italy, Turkey, Slovakia, Portugal, Greece, Saudi Arabia, Hungary, No... and more
Pfizer

Completed

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Parkinson Disease

United States, Australia, Spain, Italy, Belgium, Germany, Austria, Peru, Greece, France, Argentina, Puerto Rico, Colombia, Mexico
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

Chronic Lymphocytic Leukemia | Leukemia, B-cell | Small Lymphocytic Lymphoma | Leukemia, Lymphocytic

United States, Spain, Canada, Korea, Republic of, Taiwan, Australia, Japan, New Zealand, Italy, Czechia, China, Hungary, Israel, Belgium, France, Poland, Germany, Argentina, United Kingdom, Brazil, Turkey, Chile, Austria
Boehringer Ingelheim

Completed

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Venous Thromboembolism

United States, Korea, Republic of, Lebanon, Czechia, Saudi Arabia, Bulgaria, Serbia, Thailand, Greece, Malaysia, Vietnam, Belgium, Canada, United Kingdom, Turkey, Germany, Italy, Hungary, Latvia, Portugal, Russian Federation, Neth... and more
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Early Stage Parkinson's Disease

United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Ukraine
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Solvay Pharmaceuticals

Completed

SLV308 for Treatment of Patients With Early Parkinson's Disease

Early Stage Parkinson's Disease

United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Ukraine
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Novartis

Completed

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

Parkinson's Disease Dementia

United States, Belgium, Italy, United Kingdom, Germany, Australia, Austria, Spain, Canada, France, Netherlands, Turkey, Argentina
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom

Clinical Trials on Ovarian Neoplasms in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations